Pfizer ABRYSVO® Post-Authorisation Safety Study - Hepatically and renally impaired - VAC4EU

About
About VAC4EU

Is a not-for profit international association, with institutional memberships (study network)

Provides access to a well characterised public study network, which can provide data access and perform studies for different internal and external requesters such as vaccine manufacturers, European Commission, regulators, public health institutes.

Learn more Become a member
Organization

Vision, mission and history
Code of conduct
How we work
Governance
Members
Working groups
Collaborations
Study pipeline
- Data sources
- The VAC4EU Toolbox
Projects and Studies
Results
News
Resources
Contact us

RSV MAH-funded study Safety ABRYSVO®

Back to studies

Ongoing study

The purpose of this study is to assess the safety profile of the Pfizer RSV vaccine in renally and hepatically impaired older adults.

Lead Scientific Center

University Medical Center Utrecht

Lead Operating Centre

Fondazione Penta

Programming Expertise

University Medical Center Utrecht

Statistical Expertise

Data Expert & Access Partners

Aragon Health Sciences Institute (IACS)

Drug Safety Research Unit (DSRU)

Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)

University of Bordeaux (BPE)

Other Expertise

MediCom Consult